BusinessHemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017By Nasdaq OMXMar 6, 2017, 1:34 PM UTC
BusinessHemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017By Nasdaq OMXMar 6, 2017, 1:34 PM UTC
BusinessHemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017By Nasdaq OMXMar 6, 2017, 1:34 PM UTC
BusinessHemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in EuropeBy Nasdaq OMXJan 26, 2017, 3:51 PM UTC
BusinessHemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen® Phase III Trial in Patients with CFS/MEBy Nasdaq OMXOct 31, 2016, 12:31 PM UTC
BusinessHemispherx Biopharma Announces Completion of Ampligen® Manufacturing Technology Transfer MilestoneBy Nasdaq OMXOct 19, 2016, 12:30 PM UTC
BusinessHemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI’s 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MABy Nasdaq OMXAug 29, 2016, 12:30 PM UTC
BusinessHemispherx Biopharma Reviews Ampligen® Data With National Institute of Neurological Disorders and Stroke (NINDS)By Nasdaq OMXMar 10, 2016, 1:30 PM UTC
